Journal
JOURNAL OF ARRHYTHMIA
Volume 37, Issue 4, Pages 975-989Publisher
WILEY
DOI: 10.1002/joa3.12590
Keywords
atrial fibrillation; catheter ablation; high-power short duration; low-power long duration; meta-analysis
Categories
Ask authors/readers for more resources
The high-power short duration (HPSD) radiofrequency catheter ablation (RFCA) was found to be superior to the low-power long duration (LPLD) strategy in terms of shorter procedure time, higher first-pass pulmonary vein isolation rate, and lower recurrence rate for treating atrial fibrillation patients.
Background: Radiofrequency catheter ablation (RFCA) using the high-power short duration (HPSD) results in better ablation lesion formation in the swine model. This systematic review and meta-analysis purposed to investigate the safety and efficacy profile between HPSD and low-power long-duration (LPLD) ablation strategies to treat atrial fibrillation (AF) patients. Methods: We completed the literature review by identifying the relevant articles comparing HPSD and LPLD ablation methods for AF recorded in ClinicalTrials.com, CENTRAL, PubMed, and ScienceDirect until February 2021. The overall effects were calculated using pooled risk ratio (RR) and mean difference (MD) for categorical and continuous data, respectively. We also estimated the 95% confidence interval (CI). Results: The HPSD strategy took shorter procedure time (MD = -33.75 min; 95% CI = -44.54 to -22.97; P < .01), fluoroscopy time (MD = -5.73 min; 95% CI = -8.77 to -2.70; P < .001), and ablation time (MD = -17.71; 95% CI = -21.02 to -14.41) than LPLD strategy. The HPSD RFCA was correlated with lower risk of esophageal thermal injury (RR = 0.75; 95% CI = 0.59 to 0.94; P = .02). The HPSD method resulted in higher first-pass pulmonary vein isolation (PVI) (RR = 1.36; 95% CI = 1.13 to 1.64; P < .01), lower PV reconnection (RR = 0.47; 95% CI = 0.34 to 0.64; P < .01), and lower recurrent AF (RR = 0.72; 95% CI = 0.54 to 0.96; P = .02) than LPLD strategy. Conclusion: HPSD RFCA was superior to the conventional LPLD RFCA in terms of safety and efficacy in treating AF patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available